- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07512908
Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants (BBDIFF)
Study of Factors Influencing the Dynamicsof Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants
Clostridioides difficile (formerly C. difficile) is a bacterium found in the form of spores (a resistant form) to which patients may be exposed in a hospital environment. Once ingested, the spore can germinate in the digestive tract in its vegetative form (active form of the bacterium) and then takes on the appearance of a Gram-positive bacillus that colonizes the digestive microbiota. This preliminary stage of digestive colonization by the bacterium is facilitated by certain factors, in particular exposure to antibiotics, which disrupt the composition of the digestive microbiota (dysbiosis) and thus facilitate the establishment of C. difficile following the removal of the barrier effect of the digestive microbiota. Certain strains (known as "toxinogenic") are then able to produce the main virulence factors (toxins A (TcdA) and B (TcdB)), thereby causing the main clinical signs of digestive infection, particularly in patients with risk factors for C. difficile infection (elderly people, progressive cancer, immunodepression, etc.).The treatment of CDI is mainly based on the oral administration of anti-Clostridioides difficile antibiotics such as Fidaxomicin (FDX) or Vancomycin (VAN) for a period of 10 days, according to the European recommendations of the ESCMID and the American recommendations of the IDSA. Despite effective treatment, CDI is characterized by a high recurrence rate of up to 25% of cases, with multiple recurrences that can be particularly debilitating for patients. The effect of disruption of the gut microbiota (dysbiosis) following exposure to antibiotics can be explained by several non-exclusive hypotheses, such as the disappearance of protective bacterial species in the gut microbiota or, conversely, the appearance of bacterial species that favor the colonization of C. difficile.
Hospitalization, and more generally healthcare, has often been identified as a risk factor for CDI.Indeed, C. difficile is found ubiquitously in the environment and contaminates food products. It is still difficult to assess the frequency of contamination through the ingestion of contaminated food and the potential colonization of the host.
Only the composition of the gut microbiota appears to be an interesting avenue to explore, especially since it changes significantly during the first year of life as important events occur, including dietary diversification with the introduction of the first solid foods.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
For mothers
- Women aged 18 or over who are pregnant
- Patients who have been informed and have consented to participate in the research
- Patient affiliated with a health insurance plan (beneficiary or dependent), For minor patients (children)
- unborn child
- at least one parent of the child included is French-speaking
- written consent from both parents for participation in the study criteria for non-inclusion parents under guardianship or trusteeship parents deprived of their liberty parents under judicial protection children born under X/or in foster care
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: cohort follow-up
The only intervention will be in women with a vaginal swab.
For children, stool samples will be collected at specific points.
|
The only intervention will be in women with a vaginal swab.
For children, stool samples will be collected at specific points.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
characterize the kinetics of digestive colonization and decolonization (clearance) by C. difficile in infants
Time Frame: 18 months
|
characterize the kinetics of digestive colonization and decolonization (clearance) by C. difficile in infants from birth to 18 months of age.
|
18 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 772_BBDIFF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacteria Infection Mechanism
-
Centre of Postgraduate Medical EducationUnknownBacteria Infection MechanismPoland
-
Centre Hospitalier Universitaire de Saint EtienneRecruitingBacteria Infection MechanismFrance
-
London North West Healthcare NHS TrustCompletedSurgical Wound Infection | Intestinal Fistula | Surgical Site Infection | Intestinal Disease | Bacteria Infection MechanismUnited Kingdom
-
Azienda Sanitaria Universitaria Friuli CentraleRecruitingPiperacillin, Tazobactam Drug Combination | Bacteria InfectionItaly
-
University of CincinnatiChildren's Hospital Medical Center, CincinnatiCompleted
-
Seoul National University HospitalCompletedMultidrug-resistant Gram-negative Bacteria InfectionKorea, Republic of
-
Johanna KujalaCompletedHealthy | Drug MechanismFinland
-
Nova Scotia Health AuthorityCompleted
-
Nanjing First Hospital, Nanjing Medical UniversityNot yet recruitingInfections | Helicobacter Pylori Infection | Intestinal Bacteria Flora DisturbanceChina
-
University of British ColumbiaCompleted
Clinical Trials on cohort follow up
-
University Hospital, Clermont-FerrandRecruitingOsteoporosis, PostmenopausalFrance
-
Federico II UniversityCompletedHodgkin Lymphoma | Relapse | High Risk
-
University Hospital, ToulouseRecruiting
-
Hospices Civils de LyonCompletedDiabetes in Cystic Fibrosis PatientsFrance
-
Istanbul University - Cerrahpasa (IUC)CompletedInfertility | Psychological Distress | Infertility, Female | Depression, Anxiety | Nurse's RoleTurkey
-
University of Wisconsin, MadisonNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingRhinovirusUnited States
-
Jinling Hospital, ChinaRecruitingNeoplasms | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Carcinoma | Renal Cell Cancer | Antineoplastic Agents | Male Urogenital Diseases | Female Urogenital Diseases | Urogenital DiseasesChina
-
M.D. Anderson Cancer CenterCompletedRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Connolly Hospital BlanchardstownCompletedGeneral Surgery | Outpatients | Virtual Clinic | Text MessagingIreland
-
Centre Hospitalier Universitaire DijonRecruiting